|
|
8th
International Inter University Scientific Meeting
Academy of Studenica
NEW
TRENDS IN DIAGNOSTICS AND THERAPY OF MALIGNANT TUMORS
Organizer:
Institute of Oncology Sremska Kamenica, Yugoslavia
Co-organizers: Institute
for Oncology and Radiology, Belgrade, Yugoslavia;
"Aristotel School", Thessaloniki, Greece
President: Prof.Dr.
Vladimir Vit. Baltiæ
|
|
|
| |
IMMUNOTHERAPY
OF RENAL CELL CARCINOMA
S. Salma, V. Vit. Baltiæ, B. Nikolin
Institute of Oncology, Sremska Kamenica,
Yugoslavia
|
|
| |
ABSTRACT
Poor
prognosis of renal adenocarcinoma appears in 50% of all cases already
at the time of its diagnosis. In its metastatic form this tumor
becomes resistant to hormonal, irradiation and chemotherapy. Immunotherapy
thus has become the most important treatment modality of this disease.
The best results are achieved with alpha-interferon and interleukin-2,
applied either separately or in combination. In this study 55 patients
were treated; forty patients were given interferon only 2 to 3 times
a week in dose of 6 MIU up to the total dose of 180 MIU; fifteen
patients were treated with the combination of interferon and interleukin-2
subcutaneously during seven weeks. Clinical, biological, immunological
and toxic effects were followed up before and after the therapy.
The number of peripheral CD3,4,8 lymphocytes was determined MoAb
on Profile-II, NK toxicity according to Brunuer's method, and ELISA
assay was used for determination of antibodies to interferon. Toxic
effects were evaluated according to WHO standards (criteria).As
far as rational approach is used cytokines are safe and without
toxic effects. Subcutaneous inetrelukin-2 based therapy is accompanied
with mild side effects and within tolerant toxicity, and thus can
be applied on an outpatient basis. Interferon therapy causes constitutional,
hepatic and hematological toxic effects of lower degree. Combined
therapy results in lymphopenia (1-5 days), recurrent lymphocitosis
(6 and 7 days), the higher number of NK cells, but without significant
changes of peripheral CD3,4,8 lymphocytes. These changes are the
result of complex immunomodulated effects of interleukin-2 and interferon.
None of the prognostic factors for the most common toxicity have
been determined so far.
|
|
| |
Keywords:
Carcinoma renal cell: Immunotherapy+adwersse effects |
|
|
